A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Abroad (travel likely)Recruiting
Conditions
Primary Immunodeficiency Diseases (PID)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Takeda selected site, Tokyo, Tokyo, Japan